Active, not recruitingPhase 2NCT03029429
Theophylline Treatment for Pseudohypoparathyroidism
Studying Albright hereditary osteodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt University Medical Center
- Principal Investigator
- Ashley Shoemaker, MDVanderbilt University Medical Center
- Intervention
- Theophylline(drug)
- Enrollment
- 29 enrolled
- Eligibility
- 13-99 years · All sexes
- Timeline
- 2018 – 2026
Study locations (1)
- Ashley Shoemaker, Nashville, Tennessee, United States
Collaborators
Harvard University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03029429 on ClinicalTrials.govOther trials for Albright hereditary osteodystrophy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04551170Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years OldVanderbilt University Medical Center
- RECRUITINGNANCT00209235Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral AssessmentsConnecticut Children's Medical Center